Cellectis Romainvil (CMVLF) 11.9300 $CMVLF
Cellectis: First-Half 2014 Financial Results
Business Wire - Tue Sep 30, 1:32PM CDT
--As of September 30, available cash stands at EUR103 million
Cellectis Plant Sciences Launches Its New Website
Business Wire - Mon Sep 29, 11:00AM CDT
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering company, is proud to announce today the launch of its new website www.cellectis-plantsciences.com.
Cellectis : Individual Shareholder Meeting
Business Wire - Tue Sep 23, 11:01AM CDT
Regulatory News :
Event report: Cellectis R&D/ Analyst Day
Business Wire - Tue Sep 16, 1:49PM CDT
Regulatory News:
Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Business Wire - Thu Sep 04, 12:30AM CDT
Regulatory News:
Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology
Business Wire - Tue Sep 02, 11:31AM CDT
Regulatory News:
Pfizer's Stake in Cellectis' Capital is Welcomed by Its Shareholders
Business Wire - Thu Jul 31, 11:13AM CDT
--Cellectis SA on July 31, 2014
Cellectis divests off Swedish subsidiary for undisclosed sum to Takara Bio in Japan
M2 - Tue Jul 29, 6:24AM CDT
Cellectis SA (Paris:ALCLS.PA), a biopharmaceutical company focused on oncology, today announced the sale of its Swedish subsidiary Cellectis AB to the Japanese company Takara Bio Inc.
Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.
Business Wire - Tue Jul 29, 1:04AM CDT
Regulatory News:
Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:
Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding
ECYT: 5.95 (+0.11), DRNA: 9.90 (+0.39), SGEN: 36.37 (+0.98), ATRA: 20.24 (+2.90), ENTA: 44.97 (-0.72), ALKS: 47.62 (+1.10), NVS: 92.35 (+2.14)
Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :
Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.
Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE
FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).
PFE: 29.09 (+0.06)
Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:
Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia
Business Wire - Thu Jul 04, 11:00AM CDT
Regulatory News:
Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production
Business Wire - Wed Jun 26, 1:22PM CDT
Regulatory News:
Cellectis SA Combined General Shareholders' Meeting of June 14, 2013
Business Wire - Tue Jun 18, 11:30AM CDT
--Dr Mathieu Simon, Senior Vice President and CEO of Cellectis therapeutics, elected to the Board of Directors of Cellectis SA
Cellectis plant sciences CEO Luc Mathis joins Board of Directors of the French Association for Plant Biotechnology (AFBV)
Business Wire - Thu Jun 06, 11:42AM CDT
Regulatory News:
Cellectis: First-Half 2014 Financial Results
Business Wire - Tue Sep 30, 1:32PM CDT
--As of September 30, available cash stands at EUR103 million
Cellectis Plant Sciences Launches Its New Website
Business Wire - Mon Sep 29, 11:00AM CDT
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering company, is proud to announce today the launch of its new website www.cellectis-plantsciences.com.
Cellectis : Individual Shareholder Meeting
Business Wire - Tue Sep 23, 11:01AM CDT
Regulatory News :
Event report: Cellectis R&D/ Analyst Day
Business Wire - Tue Sep 16, 1:49PM CDT
Regulatory News:
Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Business Wire - Thu Sep 04, 12:30AM CDT
Regulatory News:
Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology
Business Wire - Tue Sep 02, 11:31AM CDT
Regulatory News:
Pfizer's Stake in Cellectis' Capital is Welcomed by Its Shareholders
Business Wire - Thu Jul 31, 11:13AM CDT
--Cellectis SA on July 31, 2014
Cellectis divests off Swedish subsidiary for undisclosed sum to Takara Bio in Japan
M2 - Tue Jul 29, 6:24AM CDT
Cellectis SA (Paris:ALCLS.PA), a biopharmaceutical company focused on oncology, today announced the sale of its Swedish subsidiary Cellectis AB to the Japanese company Takara Bio Inc.
Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.
Business Wire - Tue Jul 29, 1:04AM CDT
Regulatory News:
Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:
Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding
ECYT: 5.95 (+0.11), DRNA: 9.90 (+0.39), SGEN: 36.37 (+0.98), ATRA: 20.24 (+2.90), ENTA: 44.97 (-0.72), ALKS: 47.62 (+1.10), NVS: 92.35 (+2.14)
Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :
Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.
Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE
FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells). PFE: 29.09 (+0.06)
Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:
Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia
Business Wire - Thu Jul 04, 11:00AM CDT
Regulatory News:
Cellectis Has Successfully Engineered the Genome of Photosynthetic Algae with a View to Biofuel Production
Business Wire - Wed Jun 26, 1:22PM CDT
Regulatory News:
Cellectis SA Combined General Shareholders' Meeting of June 14, 2013
Business Wire - Tue Jun 18, 11:30AM CDT
--Dr Mathieu Simon, Senior Vice President and CEO of Cellectis therapeutics, elected to the Board of Directors of Cellectis SA
Cellectis plant sciences CEO Luc Mathis joins Board of Directors of the French Association for Plant Biotechnology (AFBV)
Business Wire - Thu Jun 06, 11:42AM CDT
Regulatory News:
